{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:42:41Z","timestamp":1766504561264},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"DOI":"10.7759\/cureus.56966","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:40:25Z","timestamp":1711467625000},"source":"Crossref","is-referenced-by-count":1,"title":["Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Sagar","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernestine Faye S","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Bellamkonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binit","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhumati","family":"Kalavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050334","article-title":"Management of multiple myeloma: a review for general practitioners in oncology","volume":"30","author":"Monteith BE","year":"2023","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023, 30:4382-401. 10.3390\/curroncol30050334","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth D","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015, 18:18-35. 10.1016\/j.drup.2014.12.001","journal-title":"Drug Resist Updat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito S","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020, 12:265. 10.3390\/cancers12020265","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen S","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C, et al.. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018, 103:1422-32. 10.3324\/haematol.2018.191288","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08023.x","article-title":"Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma","volume":"148","author":"Sinha S","year":"2010","unstructured":"Sinha S, Rajkumar SV, Lacy MQ, et al.. Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. Br J Haematol. 2010, 148:853-8. 10.1111\/j.1365-2141.2009.08023.x","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh J","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023, 13:83. 10.1038\/s41408-023-00849-z","journal-title":"Blood Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref9","unstructured":"VELCADE (Bortezomib) for Injection. (2024). Accessed. March 13, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021602s015lbl.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson PG","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al.. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005, 352:2487-98. 10.1056\/NEJMoa043445","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson PG","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, et al.. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348:2609-17. 10.1056\/NEJMoa030288","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath S","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J, et al.. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004, 127:165-72. 10.1111\/j.1365-2141.2004.05188.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials","volume":"40","author":"Das A","year":"2022","unstructured":"Das A, Dasgupta S, Gong Y, et al.. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: a network meta-analysis of randomized clinical trials. Hematol Oncol. 2022, 40:233-42. 10.1002\/hon.2959","journal-title":"Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000340050","article-title":"Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature","volume":"128","author":"Bockorny M","year":"2012","unstructured":"Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012, 128:244-7. 10.1159\/000340050","journal-title":"Acta Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2026-z","article-title":"Bortezomib-induced acute congestive heart failure: a case report and review of literature","volume":"93","author":"Subedi A","year":"2014","unstructured":"Subedi A, Sharma LR, Shah BK. Bortezomib-induced acute congestive heart failure: a case report and review of literature. Ann Hematol. 2014, 93:1797-9. 10.1007\/s00277-014-2026-z","journal-title":"Ann Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12039","article-title":"Bortezomib and heart failure: case-report and review of the French pharmacovigilance database","volume":"28","author":"Honton B","year":"2014","unstructured":"Honton B, Despas F, Dumonteil N, et al.. Bortezomib and heart failure: case-report and review of the French pharmacovigilance database. Fundam Clin Pharmacol. 2014, 28:349-52. 10.1111\/fcp.12039","journal-title":"Fundam Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos G","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, et al.. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2023, 5:1-21. 10.1016\/j.jaccao.2022.12.005","journal-title":"JACC CardioOncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241800-cyclophosphamide-bortezomib-and-dexamethasone-and-severe-systolic-heart-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:40:29Z","timestamp":1711467629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241800-cyclophosphamide-bortezomib-and-dexamethasone-and-severe-systolic-heart-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.56966","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}